anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: A composition containing rice including Milyang No. 263, rice bud, or extract thereof is provided to effectively prevent and treat alcoholism. CONSTITUTION: A composition for preventing or treating alcoholism contains rice, rice bud, or extract thereof. The rice is Milyang No. 263 containing a base of sequence number 1. The base of sequence number 1 encodes 395th amino acid into leucine after translation. The extract is prepared using water, C1-C4 alcohol, or ethyl acetate mixture solvent. A health food for preventing or treating alcoholism contains the rice, bud, or extract. [Reference numerals] (AA) Feed; (BB) General rice; (CC) Giant embryonic rice; (DD) Milyang263
Patients receive placebo PO BID starting on week 1, day 1 and continuing through 2 days after iodine I-131 therapy has been administered. Approximately 3 weeks after beginning treatment with placebo, patients receive iodine I-131 PO.
PURPOSE: A method for preparing silk fibroin of high molecular weight is provided to reduce blood glucose and cholesterol. CONSTITUTION: A composition for reducing blood glucose or cholersterol contains silk fibroin of high molecular weight as an active ingredient. The silk fibroin is 10%(w/w) silk formic acid solution with 70-350 of viscosity. The composition further contains sericin as an active ingredient. A health food for relieving or preventing diabetes, obesity, or hyperlipidemia contains the composition. A method for preparing the silk protein comprises: a step of refining silk cocoon and refining in distilled water at 90-100°C for 1-3 hours; a step of washing the refined silk cocoon using distilled water at 60-80°C; a step of dissolving the washed silk cocoon with a mixture solvent of LiBr solution or CaCl_2/water/ethanol; a step of removing salt by a cut-off tube; and a step of freeze-drying the silk protein solution.
Patients with positive PCR test results were included in the study. The age of the patient and urea, leukocyte, hemoglobin, platelet, urea, and creatinine values of the patients were recorded. Urinalysis and urine culture were taken from all patients. Acute phase reactants such as sedimentation, C-reaktif protein (CRP), ferritin, and fibrinogen were measured both at the time the patients applied and three weeks after the patient recovered. PSA and free PSA were also measured in the same way. Patients whose symptoms improved and the PCR test result was negative were considered as recovered.
The trial product is MagicTouch sirolimus drug coated balloon (Concept Medical). Sirolimus will be transferred from the balloon to the graft vein junction by inflating the balloon for 2 minutes at rated burst pressure (typically 12 to 14ATM).
Patients receive SMS-textmessage curriculum to improve self0-efficacy and self care for diabetes. A patient-identified family member receives a social support curriculum (FANS) by SMS-text-message synchronized by time and content.
The worldwide HIV/AIDS epidemic may only be controlled through development and utilization of a safe and effective vaccine that will prevent HIV infection. Due to the high prevalence of HIV-1 subtype C in southern Africa, the South African AIDS Vaccine Initiative (SAAVI), the HIV Vaccine Trials Network (HVTN) and the National Institute of Allergy and Infectious Diseases (NIAID) are evaluating two subtype C HIV vaccines, SAAVI DNA-C2 and SAAVI MVA-C through this study . These two vaccines will be used together in a prime-boost regimen. The SAAVI DNA-C2 vaccine is a multigene DNA vaccine consisting of two DNA plasmids in equal amounts that express an HIV-1 subtype C polyprotein comprising of Gag-Reverse Transcriptase-Tat-Nef and an HIV-1 subtype C truncated Env. SAAVI MVA-C is a recombinant MVA vaccine expressing the same immunogens as the SAAVI DNA-C2 vaccine. MVA is a highly attenuated vaccinia virus. The purpose of this study is to evaluate the safety and immunogenicity of an experimental DNA HIV vaccine, SAAVI DNA C2, followed by boosting with an experimental recombinant MVA HIV vaccine, SAAVI MVA-C, in HIV uninfected adults.

Participants will actively participate in this study for 12 months and will then be contacted and asked questions about their health once annually for 3 years following initial study injection. Participants will be randomly assigned to receive either the SAAVI prime-boost preventive vaccine regimen or placebo. Vaccination with the SAAVI DNA-C2 vaccine will occur at Months 0, 1, and 2; boost vaccinations with the SAAVI MVA-C vaccine will occur at Months 4 and 5. Additional study visits will occur at Weeks 2, 6, 10, 16, 18, and 20 and Days 147, 154, 273, and 364.

Study procedures include physical exams, blood and urine collection, HIV testing, an electrocardiogram, and questionnaire. Some blood collected from participants will be stored and used in future research. Risk-reduction counseling will be conducted at all study visits.
The invention relates to therapeutic preparations comprising sitosterol with a particle size of less than 30 microns. a crystalline sugar as filler, and 1 to 4% gelatine or 0.1 to 2% methyl cellulose, based on the content of sitosterol. Coarsely-powdered sitosterol is ground with the sugar to a particle size of less than 30 microns and the ground material is mixed with water containing the gelatine or methyl cellulose.  A particle size of 1-10 microns is preferred and the grinding may be done in a disc mill.  Flavouring and preservative agents may be added.  The sugar may be sucrose or lactose.  The preparation may be administered orally.
A method and apparatus for characterizing the time and frequency response of an ultrasonically reflective contrast agent is disclosed. An ultrasonically reflective contrast agent is injected, under constant pressure, into a fluid flowing through a pump flow circuit. The fluid and the ultrasonically reflective contrast agent are uniformly mixed in a mixing chamber, and the uniform mixture is passed through a contrast agent chamber. The contrast agent chamber is acoustically and axially interposed between an ultrasonic transducer chamber and an acoustic isolation chamber. A pulse of ultrasonic energy is transmitted into the contrast agent chamber from the ultrasonic transducer chamber. An echo waveform is received from the ultrasonically reflective contrast agent, and it is analyzed to determine the time and frequency response of the ultrasonically reflective contrast agent.
Patients will be instructed to perform kinesthetic motor imagery of the affected upper extremity in response to a visual cue given by the BCI system. The patients will be instructed to do motor imagery. The level of oxygenated hemoglobin (HbO) will be extracted from the ipsilesional motor cortex as the signal intensity. The signal intensity will be quantified as the percent signal change relative to the baseline. Once the signal intensity reaches the predefined individual threshold, patients will receive neurofeedback in the form of visual feedback, presented in a digital mirror therapy system. The visual feedback guides the patients to perform observational imitation using the affected upper limb. The training will last for around 75-90 minutes per session.
The expression of double-stranded RNAs (dsRNAs) from the plastid genome has been proven to be an effective method for controlling herbivorous pests by targeting essential insect genes. However, there are limitations to the efficiency of plastid-mediated RNA interference (PM-RNAi) due to the initial damage caused by the insects and their slow response to RNA interference. In this study, we developed transplastomic poplar plants that express dsRNAs targeting the β-Actin (dsACT) and Srp54k (dsSRP54K) genes of Plagiodera versicolora. Feeding experiments showed that transplastomic poplar plants can cause significantly higher mortality in P. versicolora larvae compared with nuclear transgenic or wild-type poplar plants. The efficient killing effect of PM-RNAi on P. versicolora larvae was found to be dependent on the presence of gut bacteria. Importantly, foliar application of a gut bacterial strain, Pseudomonas putida, will induce dysbiosis in the gut bacteria of P. versicolora larvae, leading to a significant acceleration in the speed of killing by PM-RNAi. Overall, our findings suggest that interfering with gut bacteria could be a promising strategy to enhance the effectiveness of PM-RNAi for insect pest control, offering a novel and effective approach for crop protection based on RNAi technology.
Care as usual means receiving their regular medical care. This consists of the regular follow up visits at the gastroenterologist every 3 months.
With economic development and overnutrition, including high-fat diets (HFD) and high-glucose diets (HGD), the incidence of obesity in children is increasing, and thus, the incidence of precocious puberty is increasing. Therefore, it is of great importance to construct a suitable animal model of overnutrition-induced precocious puberty for further in-depth study. Here, we fed a HFD, HGD, or HFD combined with a HGD to pups after P-21 weaning, while weaned pups fed a normal diet served as the control group. The results showed that HFD combined with a HGD increased the body weight (BW) of weaned rat pups. In addition, a HFD, HGD, and HFD combined with a HGD lowered the age at which vaginal opening occurred and accelerated the vaginal cell cycle. Furthermore, a HFD combined with a HGD increased the weight of the uterus and ovaries of weaned rat pups. Additionally, a HFD combined with a HGD promoted the development of reproductive organs in weaned female rat pups. Ultimately, a HFD combined with a HGD was found to elevate the serum levels of gonadotropin-releasing hormone (GnRH), luteinizing hormone (LH), follicle stimulating hormone (FSH), leptin, adiponectin, and oestradiol (E2) and increase hypothalamic GnRH, Kiss-1, and GPR54 expression levels in weaned female rat pups. The current study found that overnutrition, such as that through a HFD combined with HGD, could induce precocious puberty in weaned female rat pups. In addition, a rat model of overnutrition-induced precocious puberty was established.
<P>PROBLEM TO BE SOLVED: To provide an improved system for giving medical treatment by creating and using MAR.  <P>SOLUTION: Disclosed is a system and method for assisting with the confirmation that a correct medicament has been efficiently administered to a correct patient, at a correct dose, at a correct time, by way of a correct route. The method may include the use of a scanner to provide first, second, and third signals to a central computer (108) having data for defining a first flow and its permissible value. The first signal may include data for identifying the medicament. The second signal may include data for identifying a second flow. The third signal may include data for identifying the medicament volume in a medicament container (124). The central computer (108) recognizes the second flow if the second flow is within the permissible value of the first flow.  <P>COPYRIGHT: (C)2009,JPO&INPIT
A personal cleansing composition includes a surfactant, a thickener, emulsifier and at least one particulate dispersed in the thickener, the at least one particulate being formed of a substantially biodegradable substance. The at least one particulare may include a soy meal based polymer. The soy meal based polymer is both stable and biodegradable. The at least one particulate includes a group of suspended particles added to mechanically scrub the skin of a user or used as a textural ingredient to modify the feel, spreadability or slip of a product. The soy meal based polymer is useful in personal cleansing compositions as an exfoliant, a scrub, a film former or as a filler. The half-life of the composition may be modified as necessary based on the shelf-life of the product.
The invention discloses a small molecular peptide with analgesic effect and a specific antibody thereof. The invention provides a functional fragment, which is an amino acid fragment shown in the 872-888 th site from the N end of SEQ ID No.1 or an amino acid fragment shown in the 846-861 th site from the N end of SEQ ID No. 2. The invention also designs competitive antagonistic peptide and neutralizing antibody aiming at the functional fragment. Experiments prove that both the competitive antagonistic peptide and the neutralizing antibody have the analgesic function, but do not influence the basic pain threshold; meanwhile, the functional fragment can inhibit the growth of the axon of the neuron, and the antibody can reverse the inhibition effect of the functional fragment on the growth of the axon of the neuron. The invention provides a new idea for the research and treatment of chronic pain.
People with severe mental illness have a shorter life expectancy compared to the general population. Individuals with schizophrenia or bipolar affective disorder have an estimated reduce life expectancy by an average of 10-20 years. Increased mortality is caused by many factors, but cardiovascular diseases contributes the most. Increased prevalence of cardiovascular disease is mainly due to a poor lifestyle, which includes smoking, physical inactivity and an unhealthy diet.

It is important to find treatment that can provide better quality of life and longer life expectancy in these patient groups. Few clinical studies have been conducted on the effect of nutritional counseling on biochemical and anthropometric measurements related to cardiovascular diseases. Therefore, we want to investigate this through a randomized controlled trial.
Albumins which have been at least in part esterified or amidified are used in the production of insulin preparations. Esterification may be effected by means of diazo compounds of an aliphatic or aromatic group, or by alcohols using strong acid catalysts, or by esters, e.g. methyl esters of sulphuric acid or hydrogen halides.  Amidification may be effected by means of ammonia, amides or amines.  In examples: (1) human or ox albumin is suspended in ether and methylized by diazomethane dissolved in ether; methyl albumin is extracted from the dried reaction product by 0.01 N hydrochloric acid; (2) a 6 per cent aqueous solution of albumin is treated at 10 DEG  C. with methylamine, allowed to stand, and clarified by centrifuging, whereupon absolute alcohol is added dropwise; the amidified albumin is separated, washed with 50 per cent alcohol, dissolved in water and lyophilized at pH 4; (3) a 6 per cent aqueous albumin solution at pH 9 is treated at 40 DEG  C. with ethyl iodide, stirred, cooled to -5 DEG  C., and ethyl albumin precipitated by alcohol.ALSO:Insulin preparations with protracted effect are obtained by adding to a solution of insulin in water an animal albumin, the acid groups of which have been at least in part esterified or amidified.  Human and ox albumins are specified.  A zinc salt and a phenol, e.g. phenol itself and/or mixture of o-, m- and p-cresol, may be added to one or the mixture of the two components.  Esterification of the albumin may be effected by means of diazo compounds of an aliphatic or aromatic group, e.g. diazo methane, or by means of alcohols using strong acid catalysts or by means of esters, e.g. methyl esters of sulphuric acid or halogen halides.  Amidification may be effected by means of ammonia, amides or amines, e.g. methylamine.  Examples of such operations are given (see Group IV (b)).
Cupressus torulosa is an evergreen tree with a wide distribution in north-western Himalayan region of India. Its needles have long been used in traditional medicine for anti-inflammatory, antimicrobial, and wound-healing properties. This study aimed to scientifically validate the traditional claim of the needles to treat inflammation by evaluating the chemical composition, antioxidant potential, and anti-inflammatory activity of the essential oil extracted from the needles (CTEO) using hydro-distillation. Qualitative and quantitative chemical composition of the CTEO was determined with the aid of GC-MS and GC-FID techniques. The major constituents of the CTEO were terpinen-4-ol (393.8±12.5 μg/mg), totarol (55.0±17.2 μg/mg), and sabinene (43.7±2.8 μg/mg). CTEO exhibited significant antioxidant activity when evaluated using DPPH free radical scavenging and reducing power assays. Furthermore, the CTEO demonstrated good anti-inflammatory behavior in in vitro egg albumin denaturation assay, with an IC50 of 27.32 μg/mL. In vivo tests using carrageenan-induced paw edema and xylene-induced ear edema in rats showed significant effects at doses of 30 mg/kg for up to 1 hour. The significant discoveries not only support the established assertions about the anti-inflammatory properties of C. torulosa needles but also highlight their potential as a useful resource in the growing herbal, complementary, and alternative medicine sectors.
Disclosed are a policresulen foam agent and a preparation method, which is characterized in that raw material and excipient such as policresulen, etc. are filled into a container; a foam emulsion pump (or called foam pump or manual foam generating device) is screwed on the container; and when the emulsion pump is pressed by hand, the foams are produced. The preparation method is as following: the policresulen is added into water to be dissolved, and then polysorbate-80, sodium dodecyl sulfate and  glycerol , etc. are added into the water; the mixture is well mixed; and then distilled water is added into the mixture to the total amount; all the components are well mixed; the pH value is adjusted; the mixture is filled into the container; the foam emulsion pump (or called foam pump or  manual foam generating device) is screwed on the container; and when the  emulsion pump is pressed by hand, the foams are produced. The invention adopts drugs, emulsifier and the foam emulsion pump, and the foams are produced when the emulsion pump is pressed by hand, so the cost can be saved; environmental pollution caused by propellent can be eliminated; and at the same time, the possibilities of explosiveness of the pressure container are reduced, thereby making the pressure container safer. Therefore, the invention is a novel foam agent with simple preparation method, low price, safety and environmental protection. The policresulen foam agent can make the drugs be distributed evenly inside the vaginal canal and on the surface of skin with wide coating area, and can infiltrate into the mucosa wrinkled wall of the vaginal fast and effectively        with characteristics of exerting therapeutic effects fully and fast, good therapeutic effects, safety, sanitation and convenience. Thus, the policresulen foam agent is a good drug for treating gynecologic diseases.
In the presence of haemolysis, the interpretation of the Lactate dehydrogenase (LDH) activity result is a major operational challenge for medical laboratories: if the origin is intravascular, then the measurement will reflect the clinical reality, but in extravascular haemolysis, the laboratory will be confronted with an artefactual increase leading to false-positive high results. The aim of our study was to evaluate the adjustment of LDH concentration results according to the haemolysis index (HI). After designed a mathematical model to correct the LDH measured as a function of the haemolysis index using a Cobas 8000 analyser (Roche diagnostics, Mannheim, Germany), LDH measurement of seventy-four duplicate samples were tested before and after exposure to extravascular haemolysis process. After in vitro haemolysis process, a significant increase haemolysis index (Man-Whitney U-Test p < 0.0001) were observed. Before process the HI median was 4 [2.0 - 6.75] and after HI median was 18 [10 - 35.75]. Without correction, LDH results showed a significant increase (p < 0.001) after haemolysis process and substantial analytical discrepancies (31/74) were observed according to TEa of CLIA. After correction, data showed no significant difference (p = 0.497) and the mathematical algorithm allowed to reduce the analytical discrepancies (2/74). If haemolysis was present in vitro, the mathematical algorithm increased the accuracy of the LDH results. However, the lack of discrimination between in vivo and in vitro haemolysis requires caution and the results should be reported only as a commentary to inform the clinician.
Hypersensitivity to any component of this medication. 

Active liver disease or unexplained persistent elevations of serum transaminases (see WARNINGS).

Concomitant administration with strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, nefazodone, and cobicistat-containing products) (see Error! Hyperlink reference not valid.).

Pregnancy and lactation (see Error! Hyperlink reference not valid.and Error! Hyperlink reference not valid.). 

Atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia. Moreover, cholesterol and other products of the cholesterol biosynthesis pathway are essential components for fetal development, including synthesis of steroids and cell membranes. Because of the ability of inhibitors of HMG-CoA reductase such as lovastatin to decrease the synthesis of cholesterol and possibly other products of the cholesterol biosynthesis pathway, lovastatin is contraindicated during pregnancy and in nursing mothers. Lovastatin should be administered to women of childbearing age only when such patients are highly unlikely to conceive. If the patient becomes pregnant while taking this drug, lovastatin should be discontinued immediately and the patient should be apprised of the potential hazard to the fetus (see Error! Hyperlink reference not valid.).
A multicenter cohort of 12,000 permanent residents was recruited for routine cervical cancer screening(HPV+TCT combined screening), and the remaining specimens were collected after the conventional screening to test the indexes of high-throughput HPV typing and integrated assays. The sensitivity and accuracy of high-throughput HPV typing and integrated assays were compared with conventional screening methods.
Dengue fever is a viral illness, mainly transmitted by Aedes aegypti and Aedes albopictus. With climate change and urbanisation, more urbanised areas are becoming suitable for the survival and reproduction of dengue vector, consequently are becoming suitable for dengue transmission in China. Chongqing, a metropolis in southwestern China, has recently been hit by imported and local dengue fever, experiencing its first local outbreak in 2019. However, the genetic evolution dynamics of dengue viruses and the spatiotemporal patterns of imported and local dengue cases have not yet been elucidated. Hence, this study implemented phylogenetic analyses using genomic data of dengue viruses in 2019 and 2023 and a spatiotemporal analysis of dengue cases collected from 2013 to 2022. We sequenced a total of 15 nucleotide sequences of E genes. The dengue viruses formed separate clusters and were genetically related to those from Guangdong Province, China, and countries in Southeast Asia, including Laos, Thailand, Myanmar and Cambodia. Chongqing experienced a dengue outbreak in 2019 when 168 imported and 1,243 local cases were reported, mainly in September and October. Few cases were reported in 2013-2018, and only six were imported from 2020 to 2022 due to the COVID-19 lockdowns. Our findings suggest that dengue prevention in Chongqing should focus on domestic and overseas population mobility, especially in the Yubei and Wanzhou districts, where airports and railway stations are located, and the period between August and October when dengue outbreaks occur in endemic regions. Moreover, continuous vector monitoring should be implemented, especially during August-October, which would be useful for controlling the Aedes mosquitoes. This study is significant for defining Chongqing's appropriate dengue prevention and control strategies.